Amphastar results, outlook, call information

 Dr. Jack Zhang, Amphastar's President and Chief Executive Officer commented: "Last year was a turning point for Amphastar - with financial strength driven by the continued growth of our higher-margin products. We expect a number of pipeline milestones to be reached in 2022 as we continue to execute the Company's strategy."

Changes in net revenues were primarily driven by:

• Primatene Mist® increased volumes resulting due to the continued success of our advertising campaign

• Epinephrine sales increased due to our launch of the multi-dose vial in 2020 and higher demand for the pre-filled syringe as a result of competitor shortages

• Glucagon for injection emergency kit, which was launched in the first quarter of 2021

• Phytonadione sales increased due to an increase in unit volumes and higher average selling price

• Enoxaparin sales decreased due to lower unit volumes and lower average selling price as competitors re-entered the market in 2021

• Other finished pharmaceutical product sales increased due to higher demand, largely due to competitors' shortages

Pipeline Information

The Company currently has five ANDAs on file with the FDA targeting products with a market size of approximately $4 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and eight generic products in development targeting products with a market size of approximately $12 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2021. The Company is developing multiple proprietary products with injectable and intranasal dosage forms.

Amphastar's Chinese subsidiary, ANP, currently has 17 Drug Master Files, or DMFs, on file with the FDA and is developing several additional DMFs.

Conference Call Information

The Company will hold a conference call to discuss its financial results today, March 10, 2022, at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, five minutes before the conference.

The call can also be accessed on the Investors page on the Company's website at www.amphastar.com.

https://finance.yahoo.com/news/amphastar-pharmaceuticals-reports-financial-results-210500266.html